Journal: Journal of Nanobiotechnology

Article Title: Cerium oxide nanoparticles-carrying human umbilical cord mesenchymal stem cells counteract oxidative damage and facilitate tendon regeneration

doi: 10.1186/s12951-023-02125-5

Figure Lengend Snippet: Characterization of hUCMSCs. A Primary hUCMSCs were spindle-shaped under light microscopy. B Flow cytometry analysis showed that 98.5% of cells expressed CD29, 97.4% expressed CD44, 98.6% of cells expressed CD90, and 98.1% of cells expressed CD105. Meanwhile, only 0.48% and 0.28% expressed CD45 and CD34. C Lipid droplets were stained by oil red O after adipogenic differentiation induction of hUCMSCs. Mineralized nodules were stained by Alizarin Red after osteogenic differentiation induction of hUCMSCs. Acid mucopolysaccharide was stained by Alcian Blue after chondrogenic differentiation induction of hUCMSCs

Article Snippet: Briefly, 10 7 hUCMSCs were subjected to analysis for surface markers CD34 (E-AB-F1143D, Elabscience), CD44 (E-AB-F1100D, Elabscience), CD45 (E-AB-F1137D, Elabscience), CD29 (E-AB-F1049D, Elabscience), CD90 (E-AB-F1167D, Elabscience), and CD105 (E-AB-F1310D, Elabscience) by flow cytometry following the manufacturer’s protocol.

Techniques: Light Microscopy, Flow Cytometry, Staining

Journal: Journal of Translational Medicine

Article Title: Clinical use of Dieletrophoresis separation for live Adipose derived stem cells

doi: 10.1186/1479-5876-10-99

Figure Lengend Snippet: Schematic drawing of microelectrodes (black rectangles) trapping a stem cell (green sphere) within a DEP field (dotted lines) in the absence of any laminar flow across the array.

Article Snippet: Aliquots of pre- and post-DEP treated cells were analyzed by Guava-PCA flow cytometry using ViaCount(R) (Millipore 4000–0040 LOT 11–0115) reagent or monoclonal anti-human CD34 directly conjugated to phycoerythrin (R&D Systems FAB7227P LOT: ACOG01) according to manufacturer protocol.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Clinical use of Dieletrophoresis separation for live Adipose derived stem cells

doi: 10.1186/1479-5876-10-99

Figure Lengend Snippet: Schematic drawing of `microelectrodes (black rectangles) trapping a stem cell (green sphere) within a DEP field (dotted lines) in the presence of laminar flow (black arrows) across the array. The cell is displaced laterally to the trailing edge of the DEP field.

Article Snippet: Aliquots of pre- and post-DEP treated cells were analyzed by Guava-PCA flow cytometry using ViaCount(R) (Millipore 4000–0040 LOT 11–0115) reagent or monoclonal anti-human CD34 directly conjugated to phycoerythrin (R&D Systems FAB7227P LOT: ACOG01) according to manufacturer protocol.

Techniques:

Journal: Journal of Translational Medicine

Article Title: Clinical use of Dieletrophoresis separation for live Adipose derived stem cells

doi: 10.1186/1479-5876-10-99

Figure Lengend Snippet: Flow cytometry for detection of CD34 cells in DEP isolated SVF (lower panel) versus non-treated SVF (middle panel) and background control (upper panel).

Article Snippet: Aliquots of pre- and post-DEP treated cells were analyzed by Guava-PCA flow cytometry using ViaCount(R) (Millipore 4000–0040 LOT 11–0115) reagent or monoclonal anti-human CD34 directly conjugated to phycoerythrin (R&D Systems FAB7227P LOT: ACOG01) according to manufacturer protocol.

Techniques: Flow Cytometry, Isolation, Control

Journal: Journal of Translational Medicine

Article Title: Clinical use of Dieletrophoresis separation for live Adipose derived stem cells

doi: 10.1186/1479-5876-10-99

Figure Lengend Snippet: CD34 cell counts expressed as a percentage cell population determined by flow cytometry, before and after DEP isolation.

Article Snippet: Aliquots of pre- and post-DEP treated cells were analyzed by Guava-PCA flow cytometry using ViaCount(R) (Millipore 4000–0040 LOT 11–0115) reagent or monoclonal anti-human CD34 directly conjugated to phycoerythrin (R&D Systems FAB7227P LOT: ACOG01) according to manufacturer protocol.

Techniques: Flow Cytometry, Isolation

Journal: Cells

Article Title: IMG-A1: A Novel Immortalized Granulosa Cell Line for Investigating FSH-Dependent Folliculogenesis and Ovarian Pathophysiology

doi: 10.3390/cells14241940

Figure Lengend Snippet: Basic Characterization of the IMG-A1 Granulosa Cell Line. ( a , b ) Phase-contrast micrographs of the IMG-A1 cell culture. ( c ) Staining for senescence-associated β-galactosidase activity in passage 18 cells. ( d – f ) Immunocytochemical staining for the proliferation marker Ki67, showing a phase-contrast image ( d ), Ki67 immunofluorescence ( e ), and a merged image with DAPI nuclear counterstain ( f ). ( g , h ) Representative metaphase spreads showing a normal diploid karyotype (40 chromosomes) ( g ) and a near-tetraploid karyotype (78 chromosomes) from the IMG-A1 line ( h ). ( i – k ) Ploidy analysis by flow cytometry. Control blood cells ( i ) and primary granulosa cells ( j ) show characteristic diploid (2n) and tetraploid (4n, G2/M phase) peaks. The IMG-A1 culture ( k ) displays a predominantly near-tetraploid and near-octaploid cell population. ( l ) Flow cytometry analysis confirming the homogeneity of the IMG-A1 culture (passages 10 and 40) based on staining for the stromal marker CD29 and the absence of hematopoietic markers CD45, CD34, and the fibroblast marker CD90. Quadrant gates were set based on unstained controls. Scale bars = 100 µm.

Article Snippet: PE CD34 Rat mAb [RAM34] , Elabscience Biotechnology Co., Ltd., Wuhan, China , E-AB-F1284D.

Techniques: Cell Culture, Staining, Activity Assay, Marker, Immunofluorescence, Flow Cytometry, Control

Journal: European journal of medical research

Article Title: Olfactory mucosa-mesenchymal stem cells with overexpressed Nrf2 modulate angiogenesis and exert anti-inflammation effect in an in vitro traumatic brain injury model.

doi: 10.1186/s40001-025-02344-6

Figure Lengend Snippet: Fig. 1 Effects of OM-MSCsNrf2 on the levels of relevant cytokines in PC12 cells. A Flow cytometry was used to characterize CD45, CD34, CD29, CD90, CD73, and CD105 of OM-MSCs. B RT-qPCR-based to assess transfection efficiency after overexpression of Nrf2 plasmid. OM-MSCsNrf2: NRF2 overexpression group. OM-MSCs (ctrl): Empty vector transfection group. OM-MSCs: Untransfected OM-MSCs. C Morphology of both OM-MSCs (ctrl) and OM-MSCsNrf2 under the optical microscope. Scale bar: 100 μm. D The changes in cytokine concentrations in PC12 cells measured by ELISA, including IL4, IL10, IL13, VEGF-A, and TGF-β. Results of independent triplicates were expressed as mean ± standard deviation and the statistical difference between two groups was marked with asterisks (“ns” indicates no significant difference, *p < 0.05, and **p < 0.01). OM-MSCs olfactory mucosa-mesenchymal stem cells, Nrf2: Nuclear Factor Erythroid-Derived 2-Like 2, IL interleukin, VEGF-A vascular endothelial growth factor-A, TGF-β transforming growth factor beta

Article Snippet: Identification of OM‐MSCs The isolated OM-MSCs were stained with the following antibodies: phycoerythrin (PE)-labeled anti-CD45 antibody (#202207, 1:500, BioLegend, Inc., San Diego, CA, USA), PE/Cy5.5-labeled anti-CD34 antibody (#NBP233076PECY55, 1:500, Novus Biologicals, Centennial, CO, USA), fluorescein isothiocyanate (FITC)-labeled antiCD29 antibody (#sc-9970 FITC, 1:500, Santa Cruz Biotechnology, Dallas, TX, USA), Alexa Fluor® 647-labeled anti-CD90 antibody (#ab317534, 1:500, Abcam, Cambridge, UK), Alexa Fluor® 488-labeled anti-CD73 antibody (#NBP2-71214AF488, 1:500, Novus Biologicals, USA), and allophycocyanin (APC)-labeled anti-CD105 antibody (#NB500-452APC, 1:500, Novus Biologicals, USA) [32].

Techniques: Flow Cytometry, Quantitative RT-PCR, Transfection, Over Expression, Plasmid Preparation, Microscopy, Enzyme-linked Immunosorbent Assay, Standard Deviation, Derivative Assay

Journal: Veterinary and comparative oncology

Article Title: Canine Acute Leukemia: 50 Cases (1989 – 2014)

doi: 10.1111/vco.12251

Figure Lengend Snippet: Antibodies used for flow cytometric analysis of blood from dogs with AL

Article Snippet: 12 table ft1 table-wrap mode="anchored" t5 caption a7 Antibody Antibody Clone Source (Site) Specificity Anti-B5 antigen B5 Tompkins ‡ (NCSU) B cells Anti-CD3 CA17.2A12 AbD Serotec § (NCSU) Moore † (UGA) T cells Anti-CD4 YKIX302.9 AbD Serotec (NCSU) Helper T cells; neutrophils Anti-CD5 YKIX322.3 AbD Serotec (UGA) eBioscience § (NCSU) T cells Anti-CD8 1.140 Tompkins (NCSU) Cytotoxic T cells Anti-CD11d CA11.8H2 Novus Biologicals § (NCSU) T cells; Macrophages Anti-CD14 61D3 eBioscience (NCSU) Monocytes; Macrophages Anti-CD18 CA16.3C10 Moore (UGA) All leukocytes Anti-CD20 L26 Dako § (UGA) B cells Anti-CD21 CA21D6 AbD Serotec (NCSU) Moore (UGA) B cells Anti-CD34 BIRMA-K3 1H6 Dako (UGA) Novus Biologicals (NCSU) Hematopoietic stem cells Anti-CD45 YKIX716.13 CA12.10C12 AbD Serotec (NCSU) Moore (UGA) All leukocytes Anti-CD79b AT107-2 AbD Serotec (NCSU) B cells Open in a separate window ‡ Dr. Mary B. Tompkins, North Carolina State University, Raleigh, NC, USA § Commercial suppliers: AbD Serotec, Raleigh, NC, USA; eBioscience, San Diego, CA, USA; Novus Biologicals, Littleton, CO, USA; Dako, Carpinteria, CA, USA † Dr. Peter F. Moore, University of California, Davis, CA, USA Antibodies used for flow cytometric analysis of blood from dogs with AL Study inclusion required the following minimum AL criteria: 1) blasts constituted >20% of circulating leukocytes or >30% of the nucleated cells in the bone marrow; 2) the concurrent presence of neutropenia, anemia or thrombocytopenia; and for those definitively diagnosed as ALL, 3) confirmed lymphoid origin of leukemic cells (by flow cytometry or immunocytochemistry).

Techniques:

Journal: Veterinary and comparative oncology

Article Title: Canine Acute Leukemia: 50 Cases (1989 – 2014)

doi: 10.1111/vco.12251

Figure Lengend Snippet: The durability of responses, outcomes and putative prognostic factors for dogs with AL treated with cytotoxic chemotherapy. (A) The first remission durations for patients that had objective responses to induction cytotoxic chemotherapy are shown. Two patients that were lost to follow-up while still in remission at 16 and 130 days are censored. The median duration was 56 days. (B) The survivals of all patients treated with cytotoxic chemotherapy are shown. Five patients were lost to follow-up at 16, 16, 72, 75 and 130 days and are censored. The median survival was 55 days. (C) The survivals of patients that had objective responses to cytotoxic chemotherapy are shown. Four patients were lost to follow-up at 16, 16, 72 and 130 days and are censored. The median survival was 79 days. In (A), (B) and (C), gray lines indicate 95% confidence intervals; ticks represent censored individuals. (D) There was no significant (ns) difference in survival between patients treated with cytotoxic chemotherapy (n=29) whose circulating lymphoblasts expressed surface CD34 at initial presentation versus those negative for the antigen (Mann-Whitney U test, p=0.6769). Peripheral lymphocyte/blast counts (E) in the 2nd and 3rd, but not 4th, quartiles were associated with significantly increased hazard for decreased survival in patients treated with cytotoxic chemotherapy. Increasing age at diagnosis (F) was not associated with a significantly greater hazard for poorer survival in treated dogs. For each variable, the patient population was divided into quartiles, represented by the median value depicted on the x-axis (lymphocyte/blast count [n=36]: 6,100; 63,510; 154,600; 321,948 cells/μL; age [n=35; the age of 1 dog was not recorded]: 3; 6.4; 8.2; 10.2 years). Survival curves for each quartile were then compared to the designated reference (lowest) quartile by log-ranktest, and computed hazard ratios and their 95% confidence intervals (Mantel-Haenszel method) were plotted on the y-axis.

Article Snippet: 12 table ft1 table-wrap mode="anchored" t5 caption a7 Antibody Antibody Clone Source (Site) Specificity Anti-B5 antigen B5 Tompkins ‡ (NCSU) B cells Anti-CD3 CA17.2A12 AbD Serotec § (NCSU) Moore † (UGA) T cells Anti-CD4 YKIX302.9 AbD Serotec (NCSU) Helper T cells; neutrophils Anti-CD5 YKIX322.3 AbD Serotec (UGA) eBioscience § (NCSU) T cells Anti-CD8 1.140 Tompkins (NCSU) Cytotoxic T cells Anti-CD11d CA11.8H2 Novus Biologicals § (NCSU) T cells; Macrophages Anti-CD14 61D3 eBioscience (NCSU) Monocytes; Macrophages Anti-CD18 CA16.3C10 Moore (UGA) All leukocytes Anti-CD20 L26 Dako § (UGA) B cells Anti-CD21 CA21D6 AbD Serotec (NCSU) Moore (UGA) B cells Anti-CD34 BIRMA-K3 1H6 Dako (UGA) Novus Biologicals (NCSU) Hematopoietic stem cells Anti-CD45 YKIX716.13 CA12.10C12 AbD Serotec (NCSU) Moore (UGA) All leukocytes Anti-CD79b AT107-2 AbD Serotec (NCSU) B cells Open in a separate window ‡ Dr. Mary B. Tompkins, North Carolina State University, Raleigh, NC, USA § Commercial suppliers: AbD Serotec, Raleigh, NC, USA; eBioscience, San Diego, CA, USA; Novus Biologicals, Littleton, CO, USA; Dako, Carpinteria, CA, USA † Dr. Peter F. Moore, University of California, Davis, CA, USA Antibodies used for flow cytometric analysis of blood from dogs with AL Study inclusion required the following minimum AL criteria: 1) blasts constituted >20% of circulating leukocytes or >30% of the nucleated cells in the bone marrow; 2) the concurrent presence of neutropenia, anemia or thrombocytopenia; and for those definitively diagnosed as ALL, 3) confirmed lymphoid origin of leukemic cells (by flow cytometry or immunocytochemistry).

Techniques: MANN-WHITNEY